What question did this study set out to answer?

To investigate how the Omicron variant of SARS-CoV-2 evades neutralizing antibodies targeting the receptor-binding domain.

December 23, 2021NatureOpen Access

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

View Full Paper

Ask AI

Bookmark

To investigate how the Omicron variant of SARS-CoV-2 evades neutralizing antibodies targeting the receptor-binding domain.
Performed high-throughput yeast display screening on 247 human anti-RBD neutralizing antibodies.
Classified neutralizing antibodies into six epitope groups using unsupervised clustering.
Evaluated the neutralization impact of specific mutations found in Omicron.
Over 85% of the tested neutralizing antibodies were escaped by the Omicron variant.
Mutations like K417N and E484A significantly impaired neutralization of antibodies from groups A-D.
Antibodies with broad neutralizing activity were less affected but still escaped by certain mutations.

Authors

No takes yet. Share an insight, caveat, or question.

This randomized trial shows that Omicron largely evades neutralizing antibodies in human populations, indicating significant immune escape.

Cao et al. (2021) studied this question.

View Full Paper

Ask AI

Bookmark

This randomized trial shows that Omicron largely evades neutralizing antibodies in human populations, indicating significant immune escape.